Repatha and Praluent Launches Earn Praise From Express Scripts; Will Investors Applaud As Well?
This article was originally published in RPM Report
The first PCKS9’s aren’t setting any sales records at launch. In the current pricing climate, that is probably a good thing. For now, investors seem to agree.
Register for our free email digests: